key: cord-0836561-2ro8mfp0
authors: Yale, Katerina; Elsanadi, Rachel; Ghigi, Alessandro; Zheng, Kai; Goren, Andy; Mesinkovska, Natasha A.
title: Androgens and women: COVID‐19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism
date: 2021-03-02
journal: Int J Dermatol
DOI: 10.1111/ijd.15473
sha: d5aec9833a3bb0ee6ac0cae6402dbe2d7c08c8e7
doc_id: 836561
cord_uid: 2ro8mfp0

nan

in women with these dermatologic conditions.

The HIPAA-limited University of California COVID Research Data Set (UC CORDS) provides access to health records for patients tested for COVID-19 across UC medical institutions. 3 38) COVID-19-positive rate, none of which were different from women without these conditions (P = 0.002, P = 0.062, P = 0.635, respectively) ( Table 1) . Analysis of hospitalization rates among COVID-19-positive women (n = 4,693) in the UC CORDS indicated that 11.4% (n = 535, avg age: 41) were hospitalized within 2 weeks (1 week prior or subsequent) of testing. COVID-19-positive women with acne (n = 201) had a 4.5% (n = 9, average age: 38) hospitalization rate (P = 0.002). COVID-19-positive women with PCOS or hirsutism had 6.1% (n = 3, average age 32) and 8.0% (n = 2, average age 40) hospitalization, respectively, which was not significantly different from those without (P = 0.363, P = 1.0, respectively). Lastly, these women did not have significantly different mortality rates compared to those without these conditions (Table 1 ).

Further analysis of the populations on targeted therapies revealed no significant associations in both the COVID-19 infection rates or hospitalization rates of women with acne, PCOS, or hirsutism on spironolactone, estradiol, or metformin (P > 0.05) ( Table 2 ).

Our results suggest that there is no evidence for an Limitations include the use of a database reflective of tertiary care facilities, low case frequency, and lack of clinical details due to the de-identified database.

While androgens likely play a role in COVID-19 outcomes, there are several other sex differences to account for, like varying immune response and the potential protective effect of estrogens/progesterone. 4 Results from ongoing trials with TMPRSS2 inhibitors and anti-androgen therapy may elucidate the impact of androgens in both sexes and have a potential role in future COVID-19 management. 5 Insight on the role of sex hormones on disease incidence and severity will contribute to better understanding of at-risk populations.

Androgen sensitivity gateway to COVID-19 disease severity

Cutaneous findings and systemic associations in women with polycystic ovary syndrome

California Health Creates Centralized Data Set To Accelerate COVID-19 Research

Molecular mechanisms lead to sex-specific covid-19 prognosis and targeted therapies

Sex hormones and hormone therapy during covid-19 pandemic: implications for patients with cancer

The project described was supported by the National Center